Skip to content

Muscle Relaxation in Myopathies With Positive Muscle Phenomena

Muscle Relaxation Properties in Myopathies With Positive Muscle Phenomena: a Study Using Transcranial Magnetic Stimulation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03211923
Enrollment
30
Registered
2017-07-07
Start date
2017-01-05
Completion date
2019-12-31
Last updated
2019-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

McArdle Disease, Myotonic Dystrophy Type 2, Nemaline Myopathy Type 6

Keywords

muscle relaxation, transcranial magnetic stimulation, myopathy

Brief summary

The aim of this study is to quantify muscle relaxation properties of the finger flexor muscles in patients with different myopathies. The inhibiting effects of transcranial magnetic stimulation (TMS) on the cortical motor hand area are used to induce relaxation, which in turn will be monitored with handgrip dynamometry and EMG. The investigators will evaluate if this technique can be implemented as a diagnostic tool in clinical practice. Muscle relaxation is an often overlooked property of the muscle as compared to muscle strength or activation. Muscle relaxation is affected in different myopathies, such as myotonic dystrophy, non-dystrophic myotonias, and Brody myopathy. Therefore, a diagnostic tool to quantify muscle relaxation is of clinical and scientific importance. In this study, transcranial magnetic stimulation (TMS) is used, in combination with a dynamometer to quantify muscle relaxation properties. Transcranial magnetic stimulation (TMS) is a non-invasive technique that is commonly used to stimulate the brain. In practice, a circular coil is held directly above the scalp, upon which a strong current pulse induces a magnetic field that stimulates the underlying superficial brain areas. This stimulation can have both activating and inhibiting effects. When the motor cortex (i.e. the area of the brain that controls muscle contractions) is strongly stimulated with TMS during a voluntary muscle contraction, both excitatory and inhibitory effects can be observed in the muscle the targeted cortical area controls. The inhibitory effect entails a transient interruption of neural drive to the muscle. This interruption, called the silent period, lasts for less than half a second and results in the relaxation of the muscle. Muscle activity and control quickly return to normal after the silent period. The elegance and main advantage of TMS-induced muscle relaxation lies in the fact that it excludes all voluntary influences on the relaxation process. Furthermore, the TMS pulse causes all muscle fibres involved in the contraction just prior to the onset of the silent period to relax simultaneously. This allows us to study muscle relaxation as only a property of the muscle, i.e. without voluntary influences. In this study, the investigators will measure muscle relaxation in several myopathies (McArdle disease, Nemaline myopathy type 6 and myotonic dystrophy type 2) and compare this to healthy controls and to controls with no myopathy but with similar complaints (myalgia, stiffness, cramps). The data from these two control groups has been gathered previously in a different study. The investigators will also compare this to patients suffering from Brody disease who were previously measured in a different study. Muscle relaxation will be evaluated in fresh and fatigued finger flexor muscles. The main outcome of this study is the peak relaxation rate normalized to the peak force preceding relaxation. The final outlook of this research is to evaluate whether muscle relaxation studied with TMS, can be used for different myopathies as a diagnostic tool, to monitor disease progression, and to study the effects of different interventions (e.g. medication, exercise).

Interventions

DIAGNOSTIC_TESTTranscranial magnetic stimulation (TMS)

Single pulse, monophasic transcranial magnetic stimulation

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Diagnosis of one of the following myopathies: Nemaline myopathy type 6 (NEM6), Myotonic dystrophy type 2 (DM2), McArdle disease.

Exclusion criteria

* Pregnancy * Serious head trauma or brain surgery * Large or ferromagnetic metal parts in the head * Implanted cardiac pacemaker or neurostimulator * Epilepsy, convulsion or seizure * Use of medication that can influence muscle relaxation or cortical excitability

Design outcomes

Primary

MeasureTime frameDescription
Normalized peak relaxation rate1 hourMaximal rate at which the muscle relaxes after the TMS pulse, defined as the steepest point on the force curve. This value is normalised to the force that preceded relaxation, i.e. top of the superimposed twitch.

Secondary

MeasureTime frameDescription
Force decline at 150ms1 hourThe force decline (percentage of peak force) at 150ms after TMS stimulation.
Relaxation times (RT)1 hourThe time needed for force to decline to a certain percentage of peak force. E.g. the 75% relaxation time, is defined as the time needed for force to decline from 100% (i.e. force before relaxation onset) to 75%. Different relaxation times will be evaluated, e.g. 90% RT, 75% RT, and 50% RT
Maximal muscle strength1 hourThe highest point on the force curve prior to TMS stimulus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026